NASDAQ:CDT CDT Equity 5/14/2024 Earnings Report $2.12 +0.23 (+12.17%) Closing price 05/13/2026 03:59 PM EasternExtended Trading$2.14 +0.02 (+1.18%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CDT Equity EPS ResultsActual EPS-$15,000.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACDT Equity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACDT Equity Announcement DetailsQuarterDate5/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CDT Equity Earnings HeadlinesCDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis MarketMay 7, 2026 | globenewswire.comAnalyzing Fractyl Health (NASDAQ:GUTS) & CDT Equity (NASDAQ:CDT)May 7, 2026 | americanbankingnews.comIs this AI lab Elon’s SpaceX lifeline?Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus 1 supercomputer - all in three months. The lab saw 80x revenue and usage growth in Q1 2026 alone, when it had only planned for 10x. 60-year Wall Street veteran Marc Chaikin calls it the most important potential IPO of 2026 - and says he's found a pre-IPO backdoor trading under $40 per share. His stock-rating system previously turned bullish on Nvidia in 2014 before a nearly 50,000% run, and on Vertiv before a 3,985% surge. | Chaikin Analytics (Ad)CDT Equity (NASDAQ:CDT) Trading 8.7% Higher - Here's WhyMay 7, 2026 | americanbankingnews.comCDT Advances AZD5904 into Global Patent Phase and Initiates Partnering DiscussionsMay 6, 2026 | globenewswire.comCDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven DiscoveryApril 16, 2026 | globenewswire.comSee More CDT Equity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email. Email Address About CDT EquityConduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.View CDT Equity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesD-Wave Earnings Looked Weak, But Investors May Be Missing ThisPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?On Holdings Sets Up for Marathon Rally: New Highs Are ComingShake Shack Stock Gets Shaken After Earnings MissRocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
